Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients
Nataša Stojanović Gužvić(Fraunhofer Institute for Toxicology and Experimental Medicine), Christian Werno(Fraunhofer Institute for Toxicology and Experimental Medicine), Anke Schlenska‐Lange(Krankenhaus Barmherzige Brüder), D. Hellwig(Universitätsklinikum des Saarlandes), Jirka Grosse(University Hospital Regensburg), Adithi R. Varadarajan(SIB Swiss Institute of Bioinformatics), Florian Lüke(University Hospital Regensburg), Kathrin Weidele(Fraunhofer Institute for Toxicology and Experimental Medicine), Thomas Schamberger(University of Regensburg), Silvia Materna‐Reichelt(Fraunhofer Institute for Toxicology and Experimental Medicine), Jens Warfsmann(Fraunhofer Institute for Toxicology and Experimental Medicine), Roman Mayr(Ospedale di Bolzano), Felix Keil(University of Vienna), Florian Weber(University of Augsburg), Bernhard Polzer(Fraunhofer Institute for Toxicology and Experimental Medicine), Christoph A. Klein(University Hospital Regensburg), Kamran Honarnejad(Fraunhofer Institute for Toxicology and Experimental Medicine), Wolfgang Dietmaier(University of Regensburg), Ulrich Kaiser(University of Applied Sciences Landshut), Catherine Botteron(Fraunhofer Institute for Toxicology and Experimental Medicine), Tobias Pukrop(University Hospital Regensburg), Steffi Treitschke(Fraunhofer Institute for Toxicology and Experimental Medicine), Michael Althammer(University of Regensburg), Katja Evert(University Hospital Regensburg), Xin Lü(Northeast Forestry University), Christian Schulz(University Hospital Regensburg), Martin Hoffmann(Fraunhofer Institute for Toxicology and Experimental Medicine), Péter Ugocsai(University Hospital Regensburg), Giancarlo Feliciello(Fraunhofer Institute for Toxicology and Experimental Medicine), Andrea Coluccio(Medigene (Germany)), Stephan Seitz(University Hospital Regensburg), Daniel Heudobler(University of California San Diego)
Cited by 1
Related Papers
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2015|723